Показано 0 из 0
Дата |
---|
05:42 |
02.07.2024 |
28.06.2024 |
27.06.2024 |
25.06.2024 |
24.06.2024 |
20.06.2024 |
19.06.2024 |
18.06.2024 |
17.06.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
8.10
|
8.30
|
8.04
|
8.04
|
8.04
|
8.10
|
|
|
16 080.00
|
|
|
8.29
|
8.59
|
8.59
|
8.59
|
8.29
|
|
|
8 590.00
|
|
|
8.97
|
|
|
|
8.97
|
|
|
|
|
|
8.99
|
|
|
|
8.99
|
|
|
|
|
|
9.16
|
|
|
|
9.16
|
|
|
|
|
|
9.16
|
|
|
|
9.16
|
|
|
|
|
|
9.62
|
|
|
|
9.17
|
|
|
|
|
|
9.97
|
|
|
|
9.17
|
|
|
|
|
|
9.17
|
|
|
|
9.17
|
|
|
|
|
|
9.42
|
9.97
|
9.97
|
9.97
|
9.42
|
|
|
4 980.00
|
|
Jiangsu Recbio Technology Co Ltd is a China-based company mainly engaged in the research and development of vaccines. The Company has a portfolio of clinical-stage and pre-clinical stage vaccines, and its human papilloma virus (HPV) vaccine pipelines comprise of recombinant HPV 9-valent vaccine REC603, recombinant HPV 9-valent vaccines REC601 and REC602, recombinant HPV quadrivalent vaccine REC604a, and recombinant HPV 9-valent vaccine REC604b. The Company also involves in the development of Covid-19 vaccines. The Company mainly distributes products within domestic market.